Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
MLYS
Upturn stock ratingUpturn stock rating

Mineralys Therapeutics, Inc. Common Stock (MLYS)

Upturn stock ratingUpturn stock rating
$13.53
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: MLYS (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

8 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $36.25

1 Year Target Price $36.25

Analysts Price Target For last 52 week
$36.25Target price
Low$8.24
Current$13.53
high$18.38

Analysis of Past Performance

Type Stock
Historic Profit -32.37%
Avg. Invested days 30
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 893.55M USD
Price to earnings Ratio -
1Y Target Price 36.25
Price to earnings Ratio -
1Y Target Price 36.25
Volume (30-day avg) 8
Beta -0.18
52 Weeks Range 8.24 - 18.38
Updated Date 06/30/2025
52 Weeks Range 8.24 - 18.38
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -3.75

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -35.87%
Return on Equity (TTM) -56.31%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 551178937
Price to Sales(TTM) -
Enterprise Value 551178937
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -7.41
Shares Outstanding 65175300
Shares Floating 43490817
Shares Outstanding 65175300
Shares Floating 43490817
Percent Insiders 1.46
Percent Institutions 99.6

Analyst Ratings

Rating 3
Target Price 36.25
Buy 2
Strong Buy 6
Buy 2
Strong Buy 6
Hold -
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Mineralys Therapeutics, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

Mineralys Therapeutics is a biopharmaceutical company focused on developing therapies for hypertension and kidney disease. Founded in 2020, it aims to address unmet needs in hypertension management.

business area logo Core Business Areas

  • Aldosterone Synthase Inhibitor Development: Focuses on developing lorundrostat, an aldosterone synthase inhibitor, for the treatment of hypertension.

leadership logo Leadership and Structure

The leadership team includes Jon Congleton (CEO). The company has a board of directors overseeing its strategic direction.

Top Products and Market Share

overview logo Key Offerings

  • Lorundrostat: Lorundrostat is an aldosterone synthase inhibitor in clinical development for hypertension. It aims to lower blood pressure by reducing aldosterone production. Competitors include existing hypertension medications such as ACE inhibitors, ARBs, diuretics, and beta-blockers.

Market Dynamics

industry overview logo Industry Overview

The hypertension market is large and growing, driven by the aging population and increasing prevalence of lifestyle-related risk factors. It is characterized by established treatments and ongoing innovation.

Positioning

Mineralys is positioned as an innovator with a novel approach to hypertension treatment through aldosterone synthase inhibition. It aims to address patients who are not adequately controlled by existing therapies.

Total Addressable Market (TAM)

The global hypertension market is estimated to be worth billions of dollars. Mineralys targets a segment of this market with patients who have uncontrolled hypertension despite existing treatments.

Upturn SWOT Analysis

Strengths

  • Novel drug candidate (Lorundrostat)
  • Experienced management team
  • Focus on a large unmet medical need

Weaknesses

  • Single asset company
  • Clinical trial risk
  • Limited commercial infrastructure

Opportunities

  • Successful clinical trial results
  • Partnerships with larger pharmaceutical companies
  • Expansion into new indications

Threats

  • Competition from existing hypertension drugs
  • Regulatory hurdles
  • Failure to demonstrate efficacy or safety in clinical trials

Competitors and Market Share

competitor logo Key Competitors

  • AZN
  • NVS
  • PFE

Competitive Landscape

Mineralys faces competition from established pharmaceutical companies with broad portfolios of hypertension medications. Its competitive advantage lies in the potential for lorundrostat to address unmet needs in patients with uncontrolled hypertension.

Growth Trajectory and Initiatives

Historical Growth: Growth has been driven by the advancement of lorundrostat through clinical trials.

Future Projections: Future growth depends on the successful completion of clinical trials and potential commercialization of lorundrostat. Analyst estimates may vary significantly based on perceived risk and potential market opportunity.

Recent Initiatives: Recent initiatives include ongoing clinical trials for lorundrostat.

Summary

Mineralys Therapeutics is a clinical-stage biopharmaceutical company developing Lorundrostat for hypertension. Its success hinges on positive clinical trial outcomes. The company faces competition from established treatments and requires significant funding. A major success could lead to acquisition by a larger Pharma company or partnership with a big pharma company. It should continue to raise money and be careful not to overspend.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports
  • ClinicalTrials.gov

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on your own due diligence and consultation with a qualified financial advisor. Market share data are estimates and may vary.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Mineralys Therapeutics, Inc. Common Stock

Exchange NASDAQ
Headquaters Radnor, PA, United States
IPO Launch date 2023-02-10
President, CEO & Director Mr. Jon Congleton
Sector Healthcare
Industry Biotechnology
Full time employees 51
Full time employees 51

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.